Taurine protects against the cytotoxicity of hydrazine, 1,4-naphthoquinone and carbon tetrachloride in isolated rat hepatocytes.

Exposure of rat hepatocytes to hydrazine, carbon tetrachloride or 1,4-naphthoquinone results in cytotoxicity determined as uptake of Trypan blue and leakage of lactate dehydrogenase (LDH). After exposure of hepatocytes to hydrazine and 1,4-naphthoquinone, ATP was also measured and was found to be depleted. Addition of the beta-amino acid taurine to the hepatocyte incubation buffer partially protects the cells against the cytotoxicity of these three different cytotoxic compounds, as indicated by Trypan blue uptake and LDH leakage. Taurine also reduces the depletion of ATP caused by 1,4-naphthoquinone but not hydrazine. It is suggested that taurine may have a cytoprotective effect in vitro and may be a useful tool for the investigation of mechanisms of cytotoxicity.

Effect of hydrazine upon vitamin B12-dependent methionine synthase activity and the sulphur amino acid pathway in isolated rat hepatocytes.

The effect of the industrial chemical, hydrazine (4-12 mM), on methionine synthase (EC 2.1.1.13) activity and levels of the sulphur amino acids homocysteine, cysteine, and taurine as well as GSH were investigated in vitro in isolated rat hepatocyte suspensions and monolayers in order to explain some of the adverse in vivo effects of hydrazine. None of the concentrations of hydrazine were overtly cytotoxic in hepatocyte suspensions (measured as lactate dehydrogenase [LDH] leakage) after 3 hr. However, after 24 hr in culture cells treated with 12 mM, hydrazine showed a significant increase in LDH leakage. Methionine synthase activity was reduced by hydrazine (8 and 12 mM) in suspensions (by 45 and 55%, after 3 hr) and monolayers (12 mM; 65-80% after 24 hr). This was not due to nitric oxide production and the inhibitor of nitric oxide synthase, Nomega-nitro-L-arginine, failed to protect against the hydrazine-induced loss of ATP and GSH and the reduction in urea synthesis at 24 hr. Homocysteine export was increased by 6 mM hydrazine, and total taurine content of treated cells was increased by 12 mM hydrazine. Thus, hydrazine was found to have several important and possibly deleterious effects on some parts of the sulphur amino acid pathway.

The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage.

Administration of clenbuterol to rats in the drinking water over a 4 day period increased incorporation of [3H]leucine into muscle protein and caused a slight reduction in urinary 3-methylhistidine but did not result in an increase in body or muscle weight. However, both urinary and liver taurine were significantly reduced at the highest dose of clenbuterol (2 mg.kg-1.day-1). Serum creatine kinase, muscle isoenzyme (CK-MM) was raised and single muscle fibre injury was observed in the soleus muscle in animals treated with the middle dose (0.2 mg.kg-1.day-1) and highest dose (2 mg.kg-1.day-1). The reduction in the body pool of taurine caused by clenbuterol is of concern as taurine has been shown to have protective properties.

The correlation between urinary and liver taurine levels and between pre-dose urinary taurine and liver damage.

Analysis of data from several studies has shown that urinary taurine levels are highly significantly correlated with liver taurine concentration in control rats. Furthermore, urinary taurine levels measured before dosing with various hepatotoxic agents are significantly correlated with serum AST and ALT values measured after dosing with hepatotoxicants. That is, animals with low urinary taurine values and therefore low liver taurine concentrations tend to show greater hepatic damage. These data suggest that taurine may have a protective function in the liver.

Reduction of liver taurine in rats by beta-alanine treatment increases carbon tetrachloride toxicity.

Treatment of rats with beta-alanine increases the urinary taurine levels and markedly reduces the concentration of taurine in the liver. Dosing with carbon tetrachloride (CCl4) during treatment with beta-alanine results in a marked decrease in urinary taurine concomitant with a decrease in food intake. Treatment of animals with beta-alanine increases the hepatotoxicity of single doses of CCl4 as determined histologically and by measurement of serum alanine transaminase (ALT) and aspartate transaminase (AST) levels. Urinary creatine is also raised significantly after the administration of CCl4 in beta-alanine-treated animals. However, the accumulation of triglycerides (TRIG) in the liver caused by dosing with CCl4 was not influenced by beta-alanine treatment. The data suggest that liver taurine levels may be an important factor in determining the degree of CCl4-induced cellular necrosis but not hepatic triglyceride accumulation.

Triglyceride disposition in isolated hepatocytes after treatment with hydrazine.

Treatment of animals with hydrazine causes the accumulation of triglycerides in the liver but the mechanism remains unclear. Therefore, the effect of hydrazine on hepatic triglyceride synthesis and subsequent transport was studied in a hepatocyte model, in vitro in order to isolate liver cells from extrahepatic influences. Hepatocytes were isolated and either incubated in suspension with [14C]palmitate in the presence of hydrazine (2-12 mM) or pre-incubated with [14C]palmitate, washed free of the fatty acid and then incubated with hydrazine (2-12 mM). Hydrazine resulted in a significant reduction in the incorporation of [14C]palmitate into triglycerides and reduction in the transportation of triglycerides out of cells. When [14C]palmitate was in the incubation medium, ATP levels were reduced by lower concentrations of hydrazine than have previously been reported. None of the concentrations of hydrazine used affected cell membrane integrity (viability) as measured by LDH leakage. The 14CO2 produced by the beta-oxidation of [14C]palmitate was also measured in short term incubations (30 min) carried out in sealed vessels. There was a dose dependent increase in 14CO2 produced by very low concentrations of hydrazine (0.01-0.1 mM) after which the effect was maximal and concentrations above 8 mM hydrazine decreased 14CO2 production. The data suggest that the inhibition of transportation of triglycerides out of cells by hydrazine may have a more important role in the accumulation of triglycerides in the liver than has been previously recognised. However, the model was not able to mimic the accumulation of triglycerides in hepatocytes seen in vivo.

Cytoprotective effects of taurine in isolated rat hepatocytes.

This study examined the protection of isolated rat hepatocytes against carbon tetrachloride, hydrazine and 1,4-naphthoquinone (1,4-NQ) toxicity. Hepatocytes were incubated with various concentrations of toxicant in the presence and absence of taurine (0-15 mm). The presence of taurine significantly decreased the cytotoxicity of each compound as measured by trypan blue uptake and lactate dehydrogenase leakage. The protection was related to the concentration of taurine, with a significant effect at 10 mm for all three compounds. When ATP was measured, however, taurine failed to protect against the depletion caused by hydrazine, whereas depletion due to 1,4-NQ was significantly ameliorated. The results suggest that taurine may protect cells from cytotoxicity as reflected by membrane damage but biochemical events underlying the toxicity, such as ATP depletion, may not be affected. Taurine may be a useful tool for the investigation of mechanisms of cytotoxicity.

Correlations between in vivo and in vitro effects of toxic compounds: Studies with hydrazine.

Studies have been carried out in rats in vivo and in isolated hepatocytes from the same strain of rat in vitro using the hepatotoxicant hydrazine as a model compound. These studies have shown that a number of biochemical changes occur and are measurable in both systems. However, despite measuring the same parameters in each system, the effects do not necessarily show a quantitative or qualitative correlation. Thus depletion of glutathione and ATP occurred in both systems but required a much higher concentration in vitro. The effects on more liver-specific parameters such as triglyceride, citrulline and taurine levels in vivo were different or not observed in vitro and the inhibition of urea synthesis and cytotoxicity in vitro were not observed in vivo, although these endpoints are more relevant markers of hepatic effects. Inhibition of protein synthesis proved to be the marker that showed the best correlation, occurring at a similar concentration in vitro as in vivo, although not to the same extent. The importance of identifying specific endpoints of toxicity, the problems of comparing in vivo with in vitro data and the limitations in their interpretation are highlighted by the data presented. A knowledge of the underlying mechanisms of toxicity will clearly facilitate the design and interpretation of specific in vitro biomarkers.

Changes in taurine as an indicator of hepatic dysfunction and biochemical perturbations. Studies in vivo and in vitro.

We have shown that urinary taurine level may be used as a biomarker of pathological and biochemical lesions. Detection of changes in the urinary concentration of this low molecular weight metabolite indicates biochemical lesions which may also be associated with pathological damage. Hepatotoxic compounds such as CCl4, galactosamine and thioacetamide that cause hepatic necrosis and compounds such as hydrazine and ethionine that cause fatty liver all result in elevated urinary taurine levels in rats. However compounds which do not cause liver damage, such as cycloheximide, also raise urinary taurine levels. All of these substances are known to or are believed to inhibit protein synthesis. Conversely, compounds which increase protein synthesis, such as phenobarbital and clenbuterol, significantly decrease urinary taurine levels. Compounds which interfere with hepatic GSH synthesis will also change urinary taurine levels. Thus, depletion of GSH with diethyl maleate or phorone decreases urinary taurine whereas inhibition of GSH synthesis with compounds such as buthionine sulphoximine increases urinary taurine levels. In isolated hepatocytes in vitro, leakage of taurine occurs in response to cytotoxic compounds such as hydrazine and allyl alcohol. However, total taurine levels were increased by the hepatotoxicant CCl4. Taurine synthesis is decreased by depletion of GSH with allyl alcohol in isolated hepatocytes. Therefore taurine levels are an important potential biomarker for biochemical lesions induced by chemicals both in vivo and in vitro, in particular changes in protein and GSH synthesis.

Effect of treatment with beta-agonists on tissue and urinary taurine levels in rats. Mechanism and implications for protection.

Administration of clenbuterol to rats in the drinking water over a four day period increased incorporation of [3H]leucine into muscle protein but did not result in an increase in body or muscle weight. However, both urinary and liver taurine were significantly reduced at the highest dose of clenbuterol (2 mg.kg-1.day-1). Salbutamol also reduced urinary levels of taurine in both rats and humans. The reduction in the body pool of taurine caused by beta-agonists may be of concern as taurine has been shown to have protective properties.

Sexual dimorphism in urinary metabolite profiles of Han Wistar rats revealed by nuclear-magnetic-resonance-based metabonomics.

Gender-dependent metabolic variation in Han Wistar rats (n=25 male and n=25 female) was investigated using (1)H nuclear magnetic resonance (NMR) spectroscopy of urine coupled with chemometric methods. Statistically discriminatory regions of the spectra for male and female rats were identified and biomarker characterization was achieved by the further application of solid-phase extraction chromatography with NMR detection and high-performance liquid chromatography mass spectrometry. A novel discriminating molecule was identified as the sulfate conjugate of m-hydroxyphenylpropionic acid, which was excreted in higher concentrations by male rats. Other gender-related metabolite differences in the urine profiles included higher levels of trimethylamine-N-oxide, N,N'-dimethylglycine, m-hydroxyphenylpropionic acid, N-acetylglycoprotein, and cholate in samples from female animals. These studies emphasize the utility of multicomponent metabolic profiling for investigating physiological and genetic variation in experimental animals that may be of relevance to their use as models of toxicity and disease.

Determination of taurine in biological samples and isolated hepatocytes by high-performance liquid chromatography with fluorimetric detection.

A high-performance liquid chromatographic method with fluorimetric detection is described for the routine and selective determination of taurine in urine, serum, tissues and isolated hepatocytes. The preparation and use of ion-exchange resins to extract taurine from biological samples is included. Taurine was derivatised with o-phthalaldehyde/2-mercaptoethanol prior to injection onto a C18 column (LiChrospherR 100 RP-18, 5 microns, 125 x 4 mm I.D.). Isocratic elution of the adduct was carried out using NaH2PO4 (0.05 M, pH 5.4) in methanol and water (43:57, v/v). Homoserine was used as an internal standard to facilitate the standardisation and quantitation of samples and analysis was completed in 6 min with homoserine and taurine eluting after 3 and 4 min, respectively. The method will detect 0.5 pmol of taurine on the column. Appropriate dilutions of these biological samples enable these samples to be assayed on an autosampler, using the same standard curve. Concentrations of taurine in human, dog and rat urine, rat liver, serum and isolated hepatocytes are reported.

The biosynthesis of taurine fromN-acetyl-L-cysteine and other precursorsin vivo and in rat hepatocytes.

The synthesis of taurine fromN-acetylcysteine has been examined in ratsin vivo and in rat hepatocyte suspensionsin vitro. In ratsin vivo, administration ofN-acetylcysteine significantly increased urinary taurine (3 fold) 24h after dosing and liver glutathione levels. Liver taurine was not increased significantly. In hepatocytes incubated in the presence ofN-acetylcysteine, glutathione concentration increased to a maximum after 1 hour but the increase was not dependent on the concentration ofN-acetylcysteine. In contrast, after an initial lag phase, taurine synthesis increased in relation to the concentration ofN-acetylcysteine and continued for 3 hours. Glutathione synthesis seems to be preferential to taurine synthesis. Taurine synthesis from cysteine sulphinate was greater and from hypotaurine was greatest and maximal after 1 hour. Implications for the mechanism of protection byN-acetylcysteine are discussed.

The in vivo and in vitro protective properties of taurine.

1. Taurine is a ubiquitous, free amino acid found in mammalian systems. 2. The biological functions of taurine are unclear. 3. Various in vivo data suggest that taurine has a variety of protective functions and deficiency leads to pathological changes. 4. Depletion in rats of taurine increases susceptibility to liver damage from carbon tetrachloride. 5. Susceptibility to a variety of hepatotoxicants correlates with the estimated hepatic taurine level. 6. In vitro data suggest that taurine can protect cells against toxic damage. 7. Taurine protects isolated hepatocytes against carbon tetrachloride, hydrazine and 1,4-naphthoquinone but not against allyl alcohol, alpha-naphthylisothiocyanate (ANIT) or diaminodiphenyl methane (DAPM) cytotoxicity. 8. The mechanisms of protection are unclear but may include modulation of calcium levels, osmoregulation and membrane stabilization.

Does urinary taurine reflect changes in protein metabolism? A study with cycloheximide in rats.

Abstract We have previously reported on the changes in urinary taurine levels in rats following treatment with some hepatotoxic agents and compounds reported to affect protein synthesis. This study follows the time course of the elevation of urinary taurine after treatment of rats with cycloheximide which was maximal 8-12 h alter dosing and was dose related. [(3)H]-leucine incorporation into proteins was used as an indicator of protein synthesis. There was a significant reduction in [(3)H]-leucine incorporation into acid precipitable proteins 8 h but not 24 h after dosing. The reduction in incorporation was negatively correlated with the raised levels of both serum and urinary taurine 8 h after dosing. Liver glutathione was raised both 8 and 24 h after dosing rats and liver taurine was significantly reduced at 8 h. It is suggested that measuring urinary taurine in collections made continuously might provide a simple, non-invasive biomarker for monitoring the effects of xenobiotics or other external stimuli on the status of protein synthesis.

The effects of the beta 2-agonist drug clenbuterol on taurine levels in heart and other tissues in the rat.

The administration of a single subcutaneous dose of clenbuterol to rats altered the level of taurine in certain tissues. Taurine levels in cardiac tissue were significantly decreased 3 h after the administration of 250 micrograms/kg of clenbuterol and remained significantly depressed at 12 h post-dose only returning to control values by 24 h. The level of taurine in the liver increased 3 h after clenbuterol administration but was lower than the control value at 24 h post dose. Lung taurine levels were significantly lower than the control value at 12 hr post dose and remained depressed until 24 h post dose. Clenbuterol caused a significant increase in taurine levels in serum and muscle at 3 and 6 hr postdosing respectively but not at other time points. Serum creatine kinase (CK), activity was slightly but significantly raised at the 12 and 24 h time point. The effects of clenbuterol on tissue taurine content were not dose-dependent over the range studied (63-500 micrograms/kg). However taurine levels in the lung were significantly reduced at all doses and in the heart were significantly lower in the treated groups at all except the lowest dose, 12 h post dosing. Liver taurine levels were significantly increased at the highest dose of 500 micrograms/kg. The reduction of taurine concentrations in the heart, caused by clenbuterol, is of concern as taurine has been shown to have protective properties in many tissues especially the heart.

Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats.

The effect of various hepatotoxicants on urinary taurine and urinary creatine has been studied in the rat. Several hepatotoxic agents, carbon tetrachloride, thioacetamide, galactosamine and allyl alcohol which all caused hepatic necrosis (sometimes accompanied by steatosis), resulted in a rise in urinary taurine and in some cases creatine, when administered to rats. Ethionine and hydrazine also raised urinary taurine but caused only steatosis and did not raise urinary creatine. Therefore urinary taurine and possibly creatine may be useful markers of liver injury and dysfunction. Liver taurine levels were also affected by some of the hepatotoxicants but in those cases where there was a rise in urinary taurine this could not be accounted for by the loss in liver taurine. It is suggested that the increase in urinary taurine is partly due to changes in protein synthesis and hence in sulphur amino acid metabolism caused by hepatotoxic agents. However, bromobenzene did not increase urinary taurine and alpha-naphthylisothiocyanate and lithocholate caused reduced levels. It is suggested that this lack of increase in urinary taurine may be due to depletion of glutathione or interference with the biliary system.

Studies on the muscle toxicant 2,3,5,6-tetramethyl p-phenylenediamine: effects on various biomarkers including urinary creatine and taurine.

The effect of the specific muscle toxicant, 2,3,5,6-tetramethyl p-phenylenediamine (TMPD), on urinary creatine and taurine, markers of testicular and liver dysfunction, respectively, has been investigated in male Sprague-Dawley rats. Damage to the gastrocnemius and soleus muscles was accompanied by a rise in serum creatine kinase (predominantly the muscle-specific isoenzyme, CK-MM), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Increases in serum alpha-hydroxybutyrate dehydrogenase (HBDH) and total lactate dehydrogenase (LDH) (mainly isoenzymes, LDH1 and LDH2), occurred but only minor damage to the heart and no rise in CK-MB, (heart muscle isoenzyme) was seen. Damage to stage XIV tubules in the testis was evident histologically after the highest dose. This was accompanied by an increase in LDH-C4 testis-specific isoenzyme and a decrease in serum testosterone. Apart from reduced serum albumin, no other serum parameters indicated liver damage and there was only slight liver steatosis in some animals at the highest dose. Urinary taurine was not significantly raised after any dose of TMPD, but there was a significant increase in urinary creatine after the highest dose. It can be concluded that in the presence of discrete muscle damage, the use of urinary taurine and urinary creatine as markers of liver and testicular dysfunction, respectively, is not confounded. However, a variety of different markers should be used in conjunction to fully delineate the tissue damage due to toxic chemicals.

Effect of various non-hepatotoxic compounds on urinary and liver taurine levels in rats.

Administration of compounds which alter protein synthesis or sulphur amino acid metabolism in rats results in changes in the excretion of urinary taurine. Treatment with diethylmaleate (DEM) or phorone, which will deplete glutathione (GSH), reduces taurine excretion, whereas treatment with buthionine sulphoximine (BSO), which will inhibit glutathione synthesis, increases taurine excretion. Treatment with cycloheximide, an inhibitor of protein synthesis, increases taurine excretion, whereas pretreatment with phenobarbital, which will increase protein synthesis, decreases taurine excretion. Administration of agents which damage organs other than the liver such as the kidney, heart and testes, does not increase urinary taurine.

The inactivation of methionine synthase in isolated rat hepatocytes by sodium nitroprusside.

Methionine synthase, the enzyme that catalyses the transfer of a methyl group from 5-methyl tetrahydrofolate to homocysteine via the cofactor methylcobalamin, is one of the two established mammalian enzymes that utilise a biologically active vitamin B-12 derivative. Through its substrates, products and downstream metabolites, methionine synthase is directly involved in the sulphur amino acid pathways, polyamine biosynthesis, biological methylations and one-carbon-unit transfers. Rat liver methionine synthase was shown to be inactivated by the nitric oxide donor sodium nitroprusside. The inactivation occurred during the treatment of isolated rat hepatocytes in a time-dependent and dose-dependent manner with an apparent IC50 value of 170 microM. Highly purified rat liver methionine synthase was inactivated in a partially irreversible manner with an apparent IC50 value of 10 microM. The inactivation has been attributed to nitric oxide released by sodium nitroprusside. Since biomolecules possessing transition state metals are targets for nitric oxide, the possibility of a nitric oxide-cobalamin interaction could explain the observed inactivation. Nitric oxide is directly involved in different aspects of liver metabolic functions both under physiological and pathological conditions like sepsis and inflammation. The nitric-oxide-induced inactivation of methionine synthase could offer a rational explanation for the cellular and cytotoxic effects of this highly reactive molecule.